Japanese drugmaker Astellas and FibroGen reported that a US patient died of liver failure after taking their experimental anemia medicine known as FG-2216.
FibroGen, based in San Francisco, reported the fatality to the FDA and will discuss the cause of death and future plans for the drug with the FDA, Astellas said in a statement on its Web site. Both companies are analyzing information on the case, which involved a 76-year-old patient taking 10 other medications, according to Astellas.
FG-2216 is in Phase II testing and aims to help patients with chronic kidney disease and cancer increase levels of erythropoietin that stimulates production of red-blood cells.
FG-2216 is an oral treatment being developed as an alternative to Amgen’s Epogen and Aranesp and Johnson & Johnson’s Procrit, injectables that have been linked to deadly side effects, including strokes and heart attacks, in patients with chronic kidney failure.
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.